% stating strongly or somewhat agree | P value | ||
---|---|---|---|
Oncologists | Family physicians | ||
Whether a cancer drug is included in the National List of Health Services influences my decision regarding which cancer treatment to recommend to my patients | 77% | 54% | 0.005 |
Whether an intervention for congestive heart failure is included in the National List of Health Services influences my decision regarding which treatment to recommend to my patients | 65% | ||
Whether a cancer drug is included in the National List of Health Services highly influences my patients’ access to treatment | 92% | 84% | NS |
Whether a treatment for congestive heart failure is included in the National List of Health Services highly influences my patients’ access to treatment | 86% | ||
Every patient in Israel should have access to effective cancer treatments regardless of their cost | 65% | 55% | NS |
Every patient in Israel should have access to effective treatments for congestive heart failure regardless of their cost | 73% | 59% | NS |
Every effective cancer drug that is not included in the National List of Health Services should be included in the supplementary insurance offered by health plans | 65% | 76% | NS |
Every effective treatment for congestive heart failure that is not included in the National List of Health Services should be included in the supplementary insurance offered by health plans | 65% | 78% | NS |
Every effective cancer drug that is not included in the National List of Health Services should be included in commercial health insurance plans offered by private health insurance companies | 75% | 72% | NS |
Co-payment on cancer drugs is needed even if the drugs are included in the National List of Health Services | 10% | 10% | NS |
More research on comparative analysis of cancer drugs is needed | 83% | 85% | NS |
Data on the cost-effectiveness of new cancer drugs may have an impact on which treatment protocol to recommend to my patients | 52% | 64% | NS |
The notion that my patients will have to pay for a cancer drug “out of pocket” will influence my decision regarding which treatment protocol to recommend to my patients | 79% | 56% | NS |
How often do you discuss the costs of cancer drugs with your patients? | |||
Always | 6% | 1% | 0.007 |
Frequently | 17% | 14% | |
Occasionally | 50% | 36% | |
Rarely | 27% | 34% | |
Never | 0% | 16% | |
How often do you discuss the costs of treatments for congestive heart failure with your patients? | |||
Always | 2% | ||
Frequently | 16% | ||
Occasionally | 30% | ||
Rarely | 33% | ||
Never | 19% |